Iovance Biotherapeutics Inc
$ 2.08
-7.14%
16 Jun - close price
- Market Cap 748,012,000 USD
- Current Price $ 2.08
- High / Low $ 2.22 / 2.01
- Stock P/E N/A
- Book Value 2.30
- EPS -1.22
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.52 %
- 52 Week High 12.51
- 52 Week Low 1.64
About
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Analyst Target Price
$10.70
Quarterly Earnings
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-02-28 | 2022-11-03 | 2022-08-04 |
| Reported EPS | -0.36 | -0.26 | -0.28 | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 | -0.5 | -0.64 | -0.63 | -0.63 |
| Estimated EPS | -0.42 | -0.2676 | -0.3 | -0.35 | -0.42 | -0.43 | -0.45 | -0.8 | -0.74 | -0.64 | -0.64 | -0.61 |
| Surprise | 0.06 | 0.0076 | 0.02 | 0.01 | 0 | -0.02 | -0.01 | 0.33 | 0.24 | 0 | 0.01 | -0.02 |
| Surprise Percentage | 14.2857% | 2.8401% | 6.6667% | 2.8571% | 0% | -4.6512% | -2.2222% | 41.25% | 32.4324% | 0% | 1.5625% | -3.2787% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IOVA
2025-06-17 01:00:00
NEW YORK, June 16, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Krispy Kreme, Inc. DNUT, Strategy Incorporated MSTR, Organon & Co. OGN, and Iovance ...
2025-06-16 12:17:00
NEW YORK, June 16, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. IOVA and certain of the Company's senior executives for potential violations of the federal securities laws.
2025-06-15 17:27:00
NEW YORK, June 15, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ( "Iovance" or the "Company" ) IOVA of a class action securities lawsuit.
2025-06-15 12:00:00
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action ...
2025-06-14 12:47:00
NEW YORK, June 14, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. IOVA between May 9, 2024 and May 8, 2025, both dates inclusive ( the "Class Period" ) , of the important July 14, 2025 lead ...
2025-06-13 17:38:00
NEW YORK, June 13, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ( "Iovance" or the "Company" ) IOVA of a class action securities lawsuit.
